Literature DB >> 14605165

In vitro activities of the new antifungal drug eberconazole and three other topical agents against 200 strains of dermatophytes.

Belkys Fernández-Torres1, Isabel Inza, Josep Guarro.   

Abstract

We have compared the in vitro activity of the new antifungal drug eberconazole with those of three other topical antifungal agents, clotrimazole, ketoconazole, and miconazole, against 200 strains of dermatophytes. MICs were determined by a microdilution method with optimal conditions determined in a previous study (an inoculum of 10(4) CFU/ml, an incubation temperature of 28 degrees C, an incubation period of 7 days, and a MIC endpoint of 100% inhibition of growth). In general, the four drugs tested showed low MICs. However, eberconazole was more active (P < 0.05) than the other three drugs against the majority of the species tested. Eberconazole represents an advantageous alternative for dermatophytoses where a topical therapy is required.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605165      PMCID: PMC262513          DOI: 10.1128/JCM.41.11.5209-5211.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

Review 1.  [Use of topical antifungal agents in Spain].

Authors:  L Alou Cervera; J R Maestre Vera; R M Moreno Ubeda
Journal:  Rev Esp Quimioter       Date:  2001-12       Impact factor: 1.553

2.  Collaborative evaluation of optimal antifungal susceptibility testing conditions for dermatophytes.

Authors:  Belkys Fernández-Torres; Francisco J Cabañes; Alfonso J Carrillo-Muñoz; Alexandre Esteban; Isabel Inza; Lourdes Abarca; Josep Guarro
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

3.  Use of the sensititre colorimetric microdilution panel for antifungal susceptibility testing of dermatophytes.

Authors:  I Pujol; J Capilla; B Fernández-Torres; M Ortoneda; J Guarro
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

4.  Clinical comparison of the efficacy and tolerability of once daily Canesten with twice daily Nizoral (clotrimazole 1% cream vs. ketoconazole 2% cream) during a 28-day topical treatment of interdigital tinea pedis.

Authors:  Sigrid Suschka; Bernward Fladung; Hans F Merk
Journal:  Mycoses       Date:  2002-04       Impact factor: 4.377

Review 5.  Terbinafine. An update of its use in superficial mycoses.

Authors:  K J McClellan; L R Wiseman; A Markham
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

6.  A double-blind randomized comparative trial: eberconazole 1% cream versus clotrimazole 1% cream twice daily in Candida and dermatophyte skin infections.

Authors:  A del Palacio; F J Ortiz; A Pérez; C Pazos; M Garau; E Font
Journal:  Mycoses       Date:  2001       Impact factor: 4.377

7.  Comparative study between terbinafine 1% emulsion-gel versus ketoconazole 2% cream in tinea cruris and tinea corporis.

Authors:  A Bonifaz; A Saúl
Journal:  Eur J Dermatol       Date:  2000-03       Impact factor: 3.328

Review 8.  Six novel antimycotics.

Authors:  Adam I Rubin; Bita Bagheri; Richard K Scher
Journal:  Am J Clin Dermatol       Date:  2002       Impact factor: 7.403

9.  [Topical treatment with eberconazole of the experimental guinea pig cutaneous candidosis.].

Authors:  J M Torres-Rodríguez; N Madrenys-Brunet; L Montsant
Journal:  Rev Iberoam Micol       Date:  1999-03       Impact factor: 1.044

10.  Topical treatment of tinea corporis and tinea cruris with eberconazole (WAS 2160) cream 1% and 2%: a phase II dose-finding pilot study.

Authors:  A del Palacio; S Cuétara; A Rodríguez Noriega
Journal:  Mycoses       Date:  1995 Jul-Aug       Impact factor: 4.377

View more
  9 in total

1.  Evaluation of disk diffusion method for determining eberconazole susceptibility of dermatophytes and influence of culture medium.

Authors:  Belkys Fernández-Torres; Isabel Inza; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

2.  In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases.

Authors:  Luciana Trilles; Belkys Fernández-Torres; Márcia Dos Santos Lazéra; Bodo Wanke; Armando de Oliveira Schubach; Rodrigo de Almeida Paes; Isabel Inza; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

3.  Transcriptional profiles of the response to ketoconazole and amphotericin B in Trichophyton rubrum.

Authors:  Lu Yu; Wenliang Zhang; Lingling Wang; Jian Yang; Tao Liu; Junping Peng; Wenchuan Leng; Lihong Chen; Ruoyu Li; Qi Jin
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

4.  2-(benzylideneamino)phenol: a promising hydroxyaldimine with potent activity against dermatophytoses.

Authors:  Alan Kiill Gasparto; Ludmila Matos Baltazar; Ludmila Ferreira Gouveia; Cleiton Moreira da Silva; Ricardo Martins Duarte Byrro; Milene Alvarenga Rachid; Armando da Silva Cunha Júnior; Maria Aparecida de Resende-Stoianoff; Angelo de Fátima; Daniel Assis Santos
Journal:  Mycopathologia       Date:  2014-12-17       Impact factor: 2.574

5.  Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Task Force against Recalcitrant Tinea (ITART) Consensus on the Management of Glabrous Tinea (INTACT).

Authors:  Madhu Rengasamy; Manjunath M Shenoy; Sunil Dogra; Neelakandhan Asokan; Ananta Khurana; Shital Poojary; Jyothi Jayaraman; Ameet R Valia; Kabir Sardana; Seetharam Kolalapudi; Yogesh Marfatia; P Narasimha Rao; Ramesh M Bhat; Mahendra Kura; Deepika Pandhi; Shyamanta Barua; Vibhor Kaushal
Journal:  Indian Dermatol Online J       Date:  2020-07-13

6.  In-vitro Activity of 10 Antifungal Agents against 320 Dermatophyte Strains Using Microdilution Method in Tehran.

Authors:  Parvaneh Adimi; Seyed Jamal Hashemi; Mahmood Mahmoudi; Hossein Mirhendi; Mohammad Reza Shidfar; Masood Emmami; Ali Rezaei-Matehkolaei; Mohsen Gramishoar; Parivash Kordbacheh
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

Review 7.  Anti dermatophytic therapy--prospects for the discovery of new drugs from natural products.

Authors:  Luciana Arantes Soares; Janaína de Cássia Orlandi Sardi; Fernanda Patrícia Gullo; Nayla de Souza Pitangui; Liliana Scorzoni; Fernanda Sangalli Leite; Maria José Soares Mendes Giannini; Ana Marisa Fusco Almeida
Journal:  Braz J Microbiol       Date:  2014-03-10       Impact factor: 2.476

8.  Low in vitro activity of sertaconazole against clinical isolates of dermatophyte.

Authors:  Mahsa Behnam; Hossein Zarrinfar; Mohammad Javad Najafzadeh; Ali Naseri; Lida Jarahi; Monika Novak Babič
Journal:  Curr Med Mycol       Date:  2020

Review 9.  Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox.

Authors:  Aidan Kane; Dee A Carter
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.